Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 92

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 92
---
 to proceedings
authorized by our board of directors or brought to enforce a right to indemnification; and

●the rights conferred in the Amended Bylaws are not exclusive,
and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance
to indemnify such persons.

The outbreak of new, novel diseases, similar to the world’s
recent experience with COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.

In December 2019, a novel strain of the coronavirus disease, COVID-19,
was identified in Wuhan, China. The virus spread globally and government measures taken in response had a significant impact, both direct
and indirect, on businesses and commerce, resulting in worker shortages, disruption of supply chains, and closure of offices, laboratories,
and production facilities. Demand for certain goods and services, such as medical services and supplies, spiked, while demand for other
goods and services, such as travel, fell dramatically. If a new disease began to spread, we may experience disruptions that could severely
impact our business, including:

●interruptions in preclinical studies due to restricted or limited
operations at our laboratory facilities or at facilities of our collaborators;

●interruption of, or delays in receiving, supplies for preclinical
studies and/or clinical trials from our Contract Research Organizations (“CROs”), Contract Manufacturing Organizations (“CMOs”)
or other collaborators due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;

●limitations on employee resources that would otherwise be focused
on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire
of employees to avoid contact with large groups of people;

●interruption or delays to outsourced research and discovery
and clinical activities;

●delays in receiving authorizations from regulatory authorities
to initiate our planned clinical trials;

●delays or difficulties in commencing enrollment of patients
in our clinical trials, enrolling and retaining patients in our clinical trials in adequate numbers and difficulties in clinical site
initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

●diversion of healthcare resources away from the conduct of clinical
trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical
trials;

●interruption of key clinical trial activities, such as clinical
trial site data monitoring, due to limitations